
OpGen OPGN
Quarterly report 2025-Q3
added 11-19-2025
OpGen Depreciation & Amortization 2011-2026 | OPGN
Annual Depreciation & Amortization OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 175 K | 1.32 M | 1.64 M | 2.71 M | 2.33 M | 921 K | 731 K | 669 K | 656 K | 625 K | 574 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.71 M | 175 K | 1.12 M |
Quarterly Depreciation & Amortization OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 46 K | - | - | - | 42.2 K | - | 187 K | 188 K | 350 K | - | 182 K | 183 K | 514 K | - | 2.11 M | 1.29 M | 547 K | - | 1.62 M | 913 K | 229 K | - | 687 K | 451 K | 223 K | - | 508 K | 318 K | 156 K | - | 500 K | 324 K | 160 K | - | 495 K | 330 K | 168 K | - | 185 K | 207 K | 106 K | - | 141 K | 320 K | 162 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.11 M | 42.2 K | 433 K |
Depreciation & Amortization of other stocks in the Diagnostics research industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
321 M | $ 114.84 | -0.55 % | $ 34.9 B | ||
|
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
47.8 M | $ 16.3 | 0.62 % | $ 175 M | ||
|
Aspira Women's Health
AWH
|
112 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
1.7 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M | ||
|
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | ||
|
Biodesix
BDSX
|
5.77 M | $ 15.36 | 1.92 % | $ 1.99 B | ||
|
QIAGEN N.V.
QGEN
|
194 M | - | - | $ 10.6 B | ||
|
CareDx, Inc
CDNA
|
15 M | $ 17.82 | -2.68 % | $ 950 M | ||
|
Anixa Biosciences
ANIX
|
38.3 K | $ 2.59 | 1.57 % | $ 84.1 K | ||
|
Biomerica
BMRA
|
87 K | $ 2.17 | - | $ 4.98 M | ||
|
BioNano Genomics
BNGO
|
9.53 M | $ 1.15 | -4.17 % | $ 6.26 M | ||
|
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
1.11 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Charles River Laboratories International
CRL
|
403 M | $ 168.22 | -3.26 % | $ 8.34 B | ||
|
Castle Biosciences
CSTL
|
16 M | $ 24.73 | -0.44 % | $ 687 M | ||
|
Celcuity
CELC
|
167 K | $ 114.22 | 1.41 % | $ 5.34 B | ||
|
Danaher Corporation
DHR
|
750 M | $ 192.12 | 0.53 % | $ 137 B | ||
|
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
252 M | $ 63.21 | 1.59 % | $ 24.7 B | ||
|
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | ||
|
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
125 M | - | - | $ 19.8 B | ||
|
Quest Diagnostics Incorporated
DGX
|
570 M | $ 198.96 | 0.91 % | $ 22.1 B | ||
|
Fulgent Genetics
FLGT
|
24.9 M | $ 16.42 | -2.38 % | $ 496 M | ||
|
Guardant Health
GH
|
39.7 M | $ 89.66 | -4.44 % | $ 11.2 B | ||
|
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
587 K | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
488 M | $ 109.62 | -4.0 % | $ 9.04 B | ||
|
Interpace Biosciences
IDXG
|
425 K | $ 1.97 | 0.63 % | $ 8.72 M | ||
|
Illumina
ILMN
|
354 M | $ 127.74 | 0.28 % | $ 20.3 B | ||
|
IQVIA Holdings
IQV
|
1.14 B | $ 170.72 | -1.47 % | $ 29.3 B | ||
|
Laboratory Corporation of America Holdings
LH
|
681 M | $ 274.46 | 0.27 % | $ 22.8 B | ||
|
Lantheus Holdings
LNTH
|
70.1 M | $ 75.89 | -0.28 % | $ 5.12 B | ||
|
Medpace Holdings
MEDP
|
27.2 M | $ 496.0 | -0.47 % | $ 14.3 B | ||
|
Motus GI Holdings
MOTS
|
451 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
51.1 M | $ 1 266.63 | 0.53 % | $ 26.1 B | ||
|
Myriad Genetics
MYGN
|
53.7 M | $ 4.67 | -1.68 % | $ 432 M | ||
|
ENDRA Life Sciences
NDRA
|
44 K | $ 4.74 | 1.07 % | $ 3.73 M | ||
|
NeoGenomics
NEO
|
36.1 M | $ 8.02 | 0.25 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
119 M | $ 9.56 | 1.59 % | $ 2.07 B | ||
|
National Research Corporation
NRC
|
7.62 M | $ 17.33 | 0.99 % | $ 388 M |